Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MC4R | P32245 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778759 | 1.00 | TSHR (0.59) | TSHRCYP3A4MC4RGABRA1GABRB2 | |
| SCHEMBL20807370 | 1.00 | TSHR (0.59) | TSHRCYP3A4MC4RGABRA1GABRB2 | |
| SCHEMBL11996559 | 0.84 | TSHR (0.52) | TSHRKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL994607 | 0.83 | TSHR (0.73) | TSHRGABRA1GABRB2L3MBTL1KDM4E | |
| SCHEMBL18533077 | 0.83 | TSHR (0.50) | TSHRCYP3A4GABRA1L3MBTL1KDM4E | |
| SCHEMBL21259631 | 0.83 | TSHR (0.50) | TSHRCYP3A4GABRA1L3MBTL1KDM4E | |
| SCHEMBL780254 | 0.83 | TSHR (0.41) | TSHRCYP3A4MC4RL3MBTL1IDO1 | |
| SCHEMBL18488721 | 0.82 | CYP3A4 (0.41) | TSHRCYP3A4MC4RIDO1TDO2 | |
| SCHEMBL19388419 | 0.81 | TSHR (0.48) | TSHRCYP3A4GABRA1GABRB2L3MBTL1 | |
| SCHEMBL21259868 | 0.81 | TSHR (0.48) | TSHRCYP3A4GABRA1GABRB2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20190194182-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194182-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | TSHR 3630/4885CYP3A4 4740/4885MC4R 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.